Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.

Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.

Item
http://www.wikidata.org/entity/Q36585151
Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system.Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic reviewBiochemical characterization of uracil phosphoribosyltransferase from Mycobacterium tuberculosisImpacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.Methylation-mediated gene silencing as biomarkers of gastric cancer: a review.Impact of dihydropyrimidine dehydrogenase and γ-glutamyl hydrolase on the outcomes of patients treated with gemcitabine or S-1 as adjuvant chemotherapy for advanced pancreatic cancer.Comparison of site-specific gene expression levels in primary tumors and synchronous lymph node metastases in advanced gastric cancer.Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer.Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.The Impact of the Expression Level of Intratumoral Dihydropyrimidine Dehydrogenase on Chemotherapy Sensitivity and Survival of Patients in Gastric Cancer: A Meta-Analysis.Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric CancerMetabolomics in the fields of oncology: a review of recent research.Proteomics analysis to reveal biological pathways and predictive proteins in the survival of high-grade serous ovarian cancerTOP2A, GGH, and PECAM1 are associated with hematogenous, lymph node, and peritoneal recurrence in stage II/III gastric cancer patients enrolled in the ACTS-GC studyVariants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.A Meta-Analysis: Methylenetetrahydrofolate Reductase C677T Polymorphism in Gastric Cancer Patients Treated with 5-Fu Based Chemotherapy Predicts Serious Hematologic Toxicity but Not Prognosis.
P2860

Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.

Item
http://www.wikidata.org/entity/Q36585151
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Prediction of clinical outcome ...... luorouracil metabolic pathway.
@ast
Prediction of clinical outcome ...... luorouracil metabolic pathway.
@en
type
label
Prediction of clinical outcome ...... luorouracil metabolic pathway.
@ast
Prediction of clinical outcome ...... luorouracil metabolic pathway.
@en
prefLabel
Prediction of clinical outcome ...... luorouracil metabolic pathway.
@ast
Prediction of clinical outcome ...... luorouracil metabolic pathway.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P698
P921
P356
P1433
P1476
Prediction of clinical outcome ...... luorouracil metabolic pathway.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P5875
P698
P921